PD-1 or PD-L1 blockade acts more directly on T cells that are already activated and resides within the TME, which may be more beneficial than single-agent CTLA-4 blockade, which generally enhances T cell priming in tumour draining lymph nodes. This evidence concerns the gene CTLA4 and neoplasm.